Construction, expression and functional characterization of an engineered antibody against tumor antigen MUC-1C.


Journal

Protein expression and purification
ISSN: 1096-0279
Titre abrégé: Protein Expr Purif
Pays: United States
ID NLM: 9101496

Informations de publication

Date de publication:
11 2022
Historique:
received: 12 04 2022
revised: 02 07 2022
accepted: 20 07 2022
pubmed: 9 8 2022
medline: 30 8 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Minibodies (single-chain Fv-CH3) are fusion proteins of a single-chain variable fragment (scFv) to the human IgG1 CH3 domain. They exhibit superior properties as compared to whole antibodies due to their smaller size and less complex composition, and also as compared to scFvs due to the two antigen-binding domains, for immunotherapy and imaging of various carcinomas including breast cancer. In the current study, efficient production of the recombinant anti-MUC-1 minibody for its dominant format (VH-VL) was obtained in the periplasmic space of the Escherichia coliBL21 (DE3) expression system. The active recombinant protein was successfully purified from soluble fraction. Functional assays presented the in vitro targeting properties and specificity of the expressed anti-MUC-1 HL minibody in the MUC-1 positive cell lines compared to normal cell.

Identifiants

pubmed: 35940518
pii: S1046-5928(22)00105-X
doi: 10.1016/j.pep.2022.106148
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antigens, Neoplasm 0
Recombinant Proteins 0
Single-Chain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106148

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Mona Pourjafar (M)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran; Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.

Michaela Miehe (M)

Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.

Rezvan Najafi (R)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Meysam Soleimani (M)

Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address: m.soleymani@umsha.ac.ir.

Edzard Spillner (E)

Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark. Electronic address: e.spillner@bce.au.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH